|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-3-6
|
|
pubmed:abstractText |
This open label, multicenter study was done to evaluate the efficacy and safety of the gonadotropin hormone-releasing hormone agonist histrelin acetate administered as a 50 mg subdermal implant in men with advanced prostatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
175
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1353-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16515997-Adenocarcinoma,
pubmed-meshheading:16515997-Administration, Cutaneous,
pubmed-meshheading:16515997-Aged,
pubmed-meshheading:16515997-Aged, 80 and over,
pubmed-meshheading:16515997-Disease Progression,
pubmed-meshheading:16515997-Drug Implants,
pubmed-meshheading:16515997-Gonadotropin-Releasing Hormone,
pubmed-meshheading:16515997-Humans,
pubmed-meshheading:16515997-Male,
pubmed-meshheading:16515997-Middle Aged,
pubmed-meshheading:16515997-Prostatic Neoplasms,
pubmed-meshheading:16515997-Safety
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
|
|
pubmed:affiliation |
Department of Urology, Weill Medical College of Cornell University, New York, New York, USA. pnschleg@med.cornell.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
